Stada Arzneimittel AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Stada Arzneimittel AG with three other
pharmaceutical manufacturers in Europe:
H. Lundbeck A/S
sales of 18.12 billion Danish Kroner [US$2.69 billion]
of which 100%
Hikma Pharmaceuticals PLC
of the United Kingdom
(£1.56 billion [US$2.00 billion]
of which 40%
was Injectable Pharmaceuticals), and
based in France
(2.35 billion Euro [US$2.60 billion]
of which 82%
was Specialty Care).
Stada Arzneimittel AG reported sales of 2.33 billion Euro (US$2.58 billion)
December of 2018.
a very small
increase of 0.7%
versus 2017, when the company's sales were 2.31 billion Euro.
Sales at Stada Arzneimittel AG have increased during each of the previous five years
(and since 2013, sales have increased a total of 16%).
Sales of Generics saw an increase
that was more than double the company's growth rate: sales were up
1.6% in 2018, from
1.36 billion Euro to 1.38 billion Euro.
Not all segments of Stada Arzneimittel AG experienced an increase in sales in 2018:
sales of Branded Products fell 0.4% to 947.99 million Euro.